The largest blog for reading the latest medical research on all disease, the prevention and its treatment . Pulled from variety of sources

Monday, October 10, 2016

Doctors grapple with best use of potent new cancer drugs : reuters





as mentioned in reuters

Doctors grapple with best use of potent new cancer drugs

Doctors grapple with best use of potent new cancer drugs
Doctors grapple with best use of potent new cancer drugs
Sample analysis tubes are seen in a lab at the Institute of Cancer Research in Sutton, Britain, July 15, 2013.REUTERS/Stefan Wermuth/File PhotoCancer cells are seen on a large screen connected to a microscope at the CeBit computer fair in Hanover, Germany, March, 6, 2012.REUTERS/Fabian Bimmer/File PhotoProtein analysis tubes are seen in a lab at the Institute of Cancer Research in Sutton, Britain, July 15, 2013.REUTERS/Stefan Wermuth/File PhotoA scientist prepares protein samples for analysis in a lab at the Institute of Cancer Research in Sutton, Britain, July 15, 2013.


in addition charlotteobserver

Panthers tight end Greg Olsen advocates breast cancer screening in new babysitting video

Panthers tight end Greg Olsen advocates breast cancer screening in new babysitting video
Panthers tight end Greg Olsen advocates breast cancer screening in new babysitting video
News (and everything else) on the Carolina Panthers


as well mit

A new strategy for choosing cancer drugs

A new strategy for choosing cancer drugs
A new strategy for choosing cancer drugs
Choosing the best treatment for a cancer patient is often an inexact science.Drugs that work well for some patients may not help others, and tumors that are initially susceptible to a drug can later become resistant.In a new approach to devising more personalized treatments, researchers at MIT and Dana-Farber Cancer Institute have developed a novel way to test tumors for drug susceptibility.Using a device that measures the masses of single cells, they can predict whether a particular drug will kill tumor cells, based on how it affects their growth rates.


No comments:

Post a Comment